Compare · NTRA vs SPNE
NTRA vs SPNE
Side-by-side comparison of Natera Inc. (NTRA) and SeaSpine Holdings Corporation (SPNE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NTRA and SPNE operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA carries a market cap of $46.27B.
- NTRA has hit the wire 32 times in the past 4 weeks while SPNE has been quiet.
- NTRA has more recent analyst coverage (25 ratings vs 5 for SPNE).
- Company
- Natera Inc.
- SeaSpine Holdings Corporation
- Price
- $291.76-8.63%
- -
- Market cap
- $46.27B
- -
- 1M return
- -26.08%
- -
- 1Y return
- +41.09%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- News (4w)
- 32
- 0
- Recent ratings
- 25
- 5
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
SeaSpine Holdings Corporation
SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. The company provides orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical spine. Its orthobiologics products include demineralized bone matrices (DBM), collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to improve bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures. The company also offers orthobiologics products in various forms, such as fibers, putties, pastes, strips, and demineralized bone matrices. Its spinal implant portfolio comprises products for spinal decompression, alignment, and stabilization that are used to facilitate fusion in degenerative, minimally invasive surgery, and complex spinal deformity procedures throughout the lumbar, thoracic, and cervical spine. The company has development and licensing agreement with restor3d, Inc. and 7D Surgical, Inc. to develop 3D-printed interbody devices. SeaSpine Holdings Corporation was incorporated in 2015 and is headquartered in Carlsbad, California.
Latest NTRA
- Amendment: SEC Form SCHEDULE 13G/A filed by Natera Inc.
- CO-FOUNDER Sheena Jonathan sold $478,945 worth of shares (1,500 units at $319.30) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form S-3ASR filed by Natera Inc.
- SEC Form S-8 filed by Natera Inc.
- CO-FOUNDER Sheena Jonathan sold $975,623 worth of shares (3,086 units at $316.14) as part of a pre-agreed trading plan and sold $19,781 worth of Common Stock (64 units at $309.08) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 214,462 units (SEC Form 4)
- Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer
- Amendment: SEC Form SCHEDULE 13G/A filed by Natera Inc.
- SEC Form 10-Q filed by Natera Inc.
- Natera Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Natera Announces Leadership Transition
Latest SPNE
- SEC Form CT ORDER filed by SeaSpine Holdings Corporation
- SEC Form SC 13G/A filed by SeaSpine Holdings Corporation (Amendment)
- SEC Form 15-12G filed by SeaSpine Holdings Corporation
- SEC Form EFFECT filed by SeaSpine Holdings Corporation
- SEC Form EFFECT filed by SeaSpine Holdings Corporation
- SEC Form EFFECT filed by SeaSpine Holdings Corporation
- SEC Form 4: Stephenson Kirtley C. returned 138,340 shares to the company, closing all direct ownership in the company
- SEC Form 4: Steinway Angela returned 23,725 shares to the company, closing all direct ownership in the company
- SEC Form 4: Maniar Shweta returned 23,993 shares to the company, closing all direct ownership in the company
- SEC Form 4: Gaeta Renee returned 36,056 shares to the company, closing all direct ownership in the company